SBIA
VRTX icon

Sheaff Brock Investment Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Sheaff Brock Investment Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$705K Buy
1,454
+316
+28% +$147K 0.06% 216
2024
Q4 		$458K Buy
1,138
+29
+3% +$13.4K 0.04% 267
2024
Q3 		$516K Sell
1,109
-110
-9% -$52.8K 0.05% 248
2024
Q2 		$571K Buy
1,219
+26
+2% +$11.3K 0.05% 230
2024
Q1 		$499K Buy
1,193
+273
+30% +$115K 0.03% 289
2023
Q4 		$374K Buy
920
+17
+2% +$6.28K 0.03% 307
2023
Q3 		$314K Buy
903
+4
+0.4% +$1.4K 0.03% 319
2023
Q2 		$316K Sell
899
-52
-5% -$17.5K 0.03% 336
2023
Q1 		$300K Sell
951
-28
-3% -$8.4K 0.03% 349
2022
Q4 		$283K Sell
979
-69
-7% -$21K 0.03% 352
2022
Q3 		$303K Buy
1,048
+8
+0.8% +$2.3K 0.03% 328
2022
Q2 		$293K Buy
+1,040
New +$278K 0.02% 344

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Sheaff Brock Investment Advisors's VRTX Position: Q1 2025 in Review

Sheaff Brock Investment Advisors increased its Vertex Pharmaceuticals (VRTX) stake by 28% in Q1 2025, buying an estimated $147K and bringing the position to 1,454 shares worth $705K. The position accounts for 0.06% of the portfolio, ranked #216.

Sheaff Brock Investment Advisors first reported a position in VRTX in Q2 2022 and has held it in 12 quarters since. 1,612 funds tracked by Wall St. Rank hold VRTX as of Q1 2025.

  • Sheaff Brock Investment Advisors held 1,454 shares of Vertex Pharmaceuticals worth $705K as of Q1 2025.
  • Sheaff Brock Investment Advisors bought 316 Vertex Pharmaceuticals shares in Q1 2025, an estimated $147K.
  • Vertex Pharmaceuticals made up 0.06% of Sheaff Brock Investment Advisors's portfolio in Q1 2025, its #216 holding.
  • Sheaff Brock Investment Advisors first reported a position in Vertex Pharmaceuticals in Q2 2022 and has held it in 12 quarters since.
  • 1,612 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2025.

Based on Sheaff Brock Investment Advisors's 13F filing for Q1 2025, filed 7 May 2025.